ENABLE: CHF-PC (Comprehensive Heartcare For Patients and Caregivers)
Heart Failure, Congestive

About this trial
This is an interventional supportive care trial for Heart Failure, Congestive focused on measuring Cardiac Failure, Congestive Heart Failure, Heart Decompensation, Heart Failure, Congestive
Eligibility Criteria
Patient Inclusion Criteria:
- English-speaking and able to complete baseline interview
- Age ≥65 (Age criteria was reduced to ≥50 y/o given regional experience with HF population)
- NYHA Stage III/IV heart failure; American College of Cardiology (ACC) Class C/D
- Have a land-based phone or reliable cellular phone service
- Have an agreeable partner willing to participate in the study* (recommended) *In our previous studies we have not required patients to have a care partner for eligibility. In this study it is essential that we have an adequate number of caregivers to test the caregiver intervention. Therefore patients without a care partner will still be considered but the final study sample size may need to be adjusted to ensure an adequate caregiver sample.
Patient Exclusion Criteria:
- Non-correctable hearing loss
- Dementia or significant confusion (as measured by a Callahan score of ≤3
- Diagnostic and Statistical Manual (DSM) -IV Axis I diagnosis (e.g. schizophrenia, bipolar disorder) or active substance use disorder
Caregiver Inclusion Criteria:
- "Caregiver" is identified by the patient as "a person who knows you well and is involved in your medical care". May be a spouse or adult family member or friend living in the same household or considered by the patient to be the primary caregiver and be willing to participate."
- English-speaking and able to complete baseline interview 3. Have a land-based phone or reliable cellular phone service.
Caregiver Exclusion Criteria:
1. Non-correctable hearing loss.
Sites / Locations
- University of Alabama at Birmingham
- Dartmouth-Hitchcock Medical Center, Dartmouth College, Dartmouth-Hitchcock Heart & Vascular Center
Arms of the Study
Arm 1
Other
Summative evaluation trial of ENABLE CHF-PC
Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.